Illumina, Inc. is a global leader in sequencing and array-based solutions for genetic and genomic analysis. The company designs, manufactures, and markets integrated systems, consumables, and analysis tools that enable genetic analysis across research and clinical applications. Its portfolio supports a wide range of genomic complexity, price points, and throughput to meet customer needs in diverse markets. Illumina’s technology is foundational to advancing precision health care by enabling deeper understanding of genetic variation and function.

Illumina generates revenue primarily through the sale of sequencing and array-based instruments, consumables, and related services. Instrument sales include sequencing and array platforms sold directly to customers or through distributors. Consumable sales consist of reagents, flow cells, library preparation kits, and other kits used with its systems. Services include whole-genome sequencing, genotyping, noninvasive prenatal testing, product support, and bioinformatics solutions. In recent years, consumables have represented the largest share of revenue, followed by services and instrument sales. The company’s revenue is driven by demand from research institutions, clinical laboratories, and commercial enterprises seeking genetic analysis capabilities.

The company operates through the following segments: Core Illumina.

• Core Illumina encompasses the company’s sequencing and array-based products, consumables, services, and informatics solutions. This segment includes all activities related to genetic analysis systems used in research and clinical settings. Core Illumina supports applications in oncology, reproductive health, rare and undiagnosed diseases, agrigenomics, consumer genomics, and multi-omics research. The segment benefits from Illumina’s proprietary sequencing by synthesis chemistry, BeadArray technology, and integrated bioinformatics platforms such as BaseSpace, DRAGEN, and Illumina Connected Analytics.

Illumina holds a leading position in the life sciences tools industry, particularly in next-generation sequencing and genetic analysis markets. The company competes with other major providers of sequencing instruments, arrays, and bioinformatics tools. Its competitive advantages include proprietary technologies such as sequencing by synthesis and XLEAP-SBS chemistry, a broad and integrated product portfolio, strong intellectual property protection, and a large installed base of systems. Illumina’s focus on innovation, cost reduction, and workflow simplification has enabled it to maintain market leadership despite intense competition from established and emerging players.

Illumina serves a diverse customer base including leading genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic laboratories, and consumer genomics firms. The company’s products are used by researchers and clinicians engaged in basic and translational research, cancer genomics, reproductive health screening, infectious disease tracking, agricultural genomics, and population-scale genetic studies. Its customer base spans public and private sectors across North America, Europe, Asia-Pacific, Latin America, and other global regions.